CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model
- 29 April 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (541)
- https://doi.org/10.1126/scitranslmed.aaz2415
Abstract
Myotonic dystrophy type 1 (DM1) is an RNA-based disease with no current treatment. It is caused by a transcribed CTG repeat expansion within the 3′ untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Mutant repeat expansion transcripts remain in the nuclei of patients’ cells, forming distinct microscopically detectable foci that contribute substantially to the pathophysiology of the condition. Here, we report small-molecule inhibitors that remove nuclear foci and have beneficial effects in the HSALR mouse model, reducing transgene expression, leading to improvements in myotonia, splicing, and centralized nuclei. Using chemoproteomics in combination with cell-based assays, we identify cyclin-dependent kinase 12 (CDK12) as a druggable target for this condition. CDK12 is a protein elevated in DM1 cell lines and patient muscle biopsies, and our results showed that its inhibition led to reduced expression of repeat expansion RNA. Some of the inhibitors identified in this study are currently the subject of clinical trials for other indications and provide valuable starting points for a drug development program in DM1.This publication has 69 references indexed in Scilit:
- RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1Proceedings of the National Academy of Sciences of the United States of America, 2012
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genesGenes & Development, 2011
- Non-ATG–initiated translation directed by microsatellite expansionsProceedings of the National Academy of Sciences of the United States of America, 2010
- CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1Genes & Development, 2010
- Pentamidine reverses the splicing defects associated with myotonic dystrophyProceedings of the National Academy of Sciences of the United States of America, 2009
- Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophyProceedings of the National Academy of Sciences of the United States of America, 2009
- Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophyJCI Insight, 2007
- Increased Steady-State Levels of CUGBP1 in Myotonic Dystrophy 1 Are Due to PKC-Mediated HyperphosphorylationMolecular Cell, 2007
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophyProceedings of the National Academy of Sciences of the United States of America, 2006